The Autonomix Mission
Autonomix’s mission is to dramatically improve the quality of millions of lives by empowering the nerve-targeted treatments of tomorrow. The Company is committed to equipping physicians with innovative tools that allow for unparalleled precision in diagnosis and treatment. This means patients can look forward to more targeted treatments and a renewed sense of hope. With the Company’s groundbreaking technology, Autonomix believes they can enable new procedures that have never before been possible.
Autonomix is dedicated to transforming patient outcomes with its proprietary precision guidance technology to sense, treat and verify. Through a minimally invasive procedure and utilizing its novel nerve sensing technology, Autonomix is able to identify and target specific nerves throughout the body. Then, through its radio frequency (RF) ablation technology, it can kill responsible nerves and verify signaling has stopped. This approach has the potential to revolutionize therapeutic electrophysiology and can be applied across a number of diseases from chronic pain management to hypertension and cardiology.
Our Precision Approach to Pain Management
Autonomix Medical, Inc. is a medical device company developing precision nerve-targeted therapies to transform treatment of peripheral nervous system diseases.
The Company’s first-in-class platform technology utilizes a proprietary, catheter-based microchip sensing array that we believe surpasses other sensing technology available today and sets a new standard in neural signal detection. For the first time ever, the sensing technology enables the ability to detect and differentiate neural signals by combining ultra-high sensitivity with data processing performed directly at the point of detection. Once target nerves are identified, Autonomix uses its proprietary radio frequency (RF) ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology.
Autonomix is initially developing its precision nerve-targeted technology for the treatment of pain associated with pancreatic cancer. Initial results from the Company’s ongoing first-in-human study have shown clinically meaningful and durable pain reduction in the initial phase of the study. By delivering targeted ablation transvascularly through the vessel wall, Autonomix has demonstrated success in pancreatic cancer pain which opens up the possibility of transformative denervation treatment across a number of disease categories including hypertension, chronic pain, cardiology, pulmonology, and gastroenterology through a single, first-in-class platform technology.
* Data on File